Endogenously expressed IL-13Rα2 attenuates IL-13- mediated responses but does not activate signaling in human lung fibroblasts

Journal of Immunology

Volumn 193, Issue 1, 2014, Pages 111-119

  Chandriani, Sanjay ^a,c   DePianto, Daryle J ^a   N'Diaye, Elsa N ^a   Abbas, Alexander R ^a   Jackman, Janet ^a   Bevers III, Jack ^a   Ramirez Carrozzi, Vladimir ^a   Pappu, Rajita ^a   Kauder, Steven E ^a   Toy, Karen ^a   Ha, Connie ^a   Modrusan, Zora ^a   Wu, Lawren C ^a   Collard, Harold R ^b   Wolters, Paul J ^b   Egen, Jackson G ^a   Arron, Joseph R ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4; STAT6 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; FIBROSING ALVEOLITIS; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERLEUKIN 13 GENE; LUNG FIBROBLAST; LUNG PARENCHYMA; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; LUNG; MACROPHAGES; MALE; MONOCYTES; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903626965     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301761     Document Type: Article

References (46)

1. King, T. E., Jr., A. Pardo, and M. Selman. 2011. Idiopathic pulmonary fibrosis. Lancet 378: 1949-1961.
2. Raghu, G., H. R. Collard, J. J. Egan, F. J. Martinez, J. Behr, K. K. Brown, T. V. Colby, J. F. Cordier, K. R. Flaherty, J. A. Lasky, et al ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. 2011. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183: 788-824.
3. Raghu, G., D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster. 2006. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174: 810-816. (Pubitemid 44511663)
4. Leslie, K. O. 2012. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch. Pathol. Lab. Med. 136: 591-600.
5. Wynn, T. A. 2011. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208: 1339-1350.
6. Jakubzick, C., S. L. Kunkel, R. K. Puri, and C. M. Hogaboam. 2004. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol. Res. 30: 339-349. (Pubitemid 39546234)
7. Park, S. W., M. H. Ahn, H. K. Jang, A. S. Jang, D. J. Kim, E. S. Koh, J. S. Park, S. T. Uh, Y. H. Kim, J. S. Park, et al. 2009. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J. Korean Med. Sci. 24: 614-620.
8. Selman, M., A. Pardo, L. Barrera, A. Estrada, S. R. Watson, K. Wilson, N. Aziz, N. Kaminski, and A. Zlotnik. 2006. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 173: 188-198. (Pubitemid 43187891)
9. Zhu, Z., R. J. Homer, Z. Wang, Q. Chen, G. P. Geba, J. Wang, Y. Zhang, and J. A. Elias. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103: 779-788. (Pubitemid 29152623)
10. Zheng, T., Z. Zhu, Z. Wang, R. J. Homer, B. Ma, R. J. Riese, Jr., H. A. Chapman, Jr., S. D. Shapiro, and J. A. Elias. 2000. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J. Clin. Invest. 106: 1081-1093.
11. Lee, C. G., R. J. Homer, Z. Zhu, S. Lanone, X. Wang, V. Koteliansky, J. M. Shipley, P. Gotwals, P. Noble, Q. Chen, et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor b1. J. Exp. Med. 194: 809-821. (Pubitemid 32983016)
12. Belperio, J. A., M. Dy, M. D. Burdick, Y. Y. Xue, K. Li, J. A. Elias, and M. P. Keane. 2002. Interaction of IL-13 and C10 in the pathogenesis of bleomycininduced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 27: 419-427.
13. Chiaramonte, M. G., D. D. Donaldson, A. W. Cheever, and T. A. Wynn. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 104: 777-785. (Pubitemid 29536363)
14. Kolodsick, J. E., G. B. Toews, C. Jakubzick, C. Hogaboam, T. A. Moore, A. McKenzie, C. A. Wilke, C. J. Chrisman, and B. B. Moore. 2004. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4- deficient, mice results from impaired collagen synthesis by fibroblasts. J. Immunol. 172: 4068-4076. (Pubitemid 38375218)
15. Liu, T., H. Jin, M. Ullenbruch, B. Hu, N. Hashimoto, B. Moore, A. McKenzie, N.W. Lukacs, and S. H. Phan. 2004. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J. Immunol. 173: 3425-3431. (Pubitemid 39142053)
16. Ramalingam, T. R., J. T. Pesce, F. Sheikh, A. W. Cheever, M. M. Mentink-Kane, M. S. Wilson, S. Stevens, D. M. Valenzuela, A. J. Murphy, G. D. Yancopoulos, et al. 2008. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor a1 chain. Nat. Immunol. 9: 25-33. (Pubitemid 350286200)
17. Goenka, S., and M. H. Kaplan. 2011. Transcriptional regulation by STAT6. Immunol. Res. 50: 87-96.
18. Doherty, T. A., N. Khorram, K. Sugimoto, D. Sheppard, P. Rosenthal, J. Y. Cho, A. Pham, M. Miller, M. Croft, and D. H. Broide. 2012. Alternaria induces STAT6-dependent acute airway eosinophilia and epithelial FIZZ1 expression that promotes airway fibrosis and epithelial thickness. J. Immunol. 188: 2622-2629.
19. Lupardus, P. J., M. E. Birnbaum, and K. C. Garcia. 2010. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Rα2. Structure 18: 332-342.
20. Yasunaga, S., N. Yuyama, K. Arima, H. Tanaka, S. Toda, M. Maeda, K. Matsui, C. Goda, Q. Yang, Y. Sugita, et al. 2003. The negative-feedback regulation of the IL-13 signal by the IL-13 receptor α2 chain in bronchial epithelial cells. Cytokine 24: 293-303. (Pubitemid 37373665)
21. Zheng, T., W. Liu, S. Y. Oh, Z. Zhu, B. Hu, R. J. Homer, L. Cohn, M. J. Grusby, and J. A. Elias. 2008. IL-13 receptor α2 selectively inhibits IL-13-induced responses in the murine lung. J. Immunol. 180: 522-529.
22. Yoshikawa, M., T. Nakajima, T. Tsukidate, K. Matsumoto, M. Iida, N. Otori, S. Haruna, H. Moriyama, and H. Saito. 2003. TNF-α and IL-4 regulate expression of IL-13 receptor a2 on human fibroblasts. Biochem. Biophys. Res. Commun. 312: 1248-1255. (Pubitemid 37490951)
23. Fichtner-Feigl, S.,W. Strober, K. Kawakami, R. K. Puri, and A. Kitani. 2006. IL- 13 signaling through the IL-13α2 receptor is involved in induction of TGF-b1 production and fibrosis. Nat. Med. 12: 99-106. (Pubitemid 43050083)
24. Fichtner-Feigl, S., C. A. Young, A. Kitani, E. K. Geissler, H. J. Schlitt, and W. Strober. 2008. IL-13 signaling via IL-13Rα2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 135: 2003-2013.
25. Mandal, D., and A. D. Levine. 2010. Elevated IL-13Rα2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm. Bowel Dis. 16: 753-764.
26. Mentink-Kane, M. M., A. W. Cheever, R. W. Thompson, D. M. Hari, N. B. Kabatereine, B. J. Vennervald, J. H. Ouma, J. K. Mwatha, F. M. Jones, D. D. Donaldson, et al. 2004. IL-13 receptor α2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc. Natl. Acad. Sci. USA 101: 586-590. (Pubitemid 38084680)
27. Mentink-Kane, M. M., A. W. Cheever, M. S. Wilson, S. K. Madala, L. M. Beers, T. R. Ramalingam, and T. A. Wynn. 2011. Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL- 13Rα2. Gastroenterology 141: 2200-2209.
28. Baglole, C. J., S. Y. Reddy, S. J. Pollock, S. E. Feldon, P. J. Sime, T. J. Smith, and R. P. Phipps. 2005. Isolation and phenotypic characterization of lung fibroblasts. Methods Mol. Med. 117: 115-127.
29. Ultsch, M., J. Bevers, G. Nakamura, R. Vandlen, R. F. Kelley, L. C. Wu, and C. Eigenbrot. 2013. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J. Mol. Biol. 425: 1330-1339.
30. Corren, J., R. F. Lemanske, N. A. Hanania, P. E. Korenblat, M. V. Parsey, J. R. Arron, J. M. Harris, H. Scheerens, L. C. Wu, Z. Su, et al. 2011. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365: 1088-1098.
31. McKenzie, A. N., J. A. Culpepper, R. de Waal Malefyt, F. Brière, J. Punnonen, G. Aversa, A. Sato, W. Dang, B. G. Cocks, S. Menon, et al. 1993. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. USA 90: 3735-3739. (Pubitemid 23111442)
32. Woodruff, P. G., B. Modrek, D. F. Choy, G. Jia, A. R. Abbas, A. Ellwanger, L. L. Koth, J. R. Arron, and J. V. Fahy. 2009. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180: 388-395.
33. Choy, D. F., B. Modrek, A. R. Abbas, S. Kummerfeld, H. F. Clark, L. C. Wu, G. Fedorowicz, Z. Modrusan, J. V. Fahy, P. G. Woodruff, and J. R. Arron. 2011. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J. Immunol. 186: 1861-1869.
34. Scheerens, H., J. R. Arron, D. F. Choy, S. Mosesova, P. Lal, and J. G. Matthews. 2012. Lebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostin. Am. J. Respir. Crit. Care Med. 185: A3960.
35. Okamoto, M., T. Hoshino, Y. Kitasato, Y. Sakazaki, T. Kawayama, K. Fujimoto, K. Ohshima, H. Shiraishi, M. Uchida, J. Ono, et al. 2011. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur. Respir. J. 37: 1119-1127.
36. Prasse, A., D. V. Pechkovsky, G. B. Toews, M. Schäfer, S. Eggeling, C. Ludwig, M. Germann, F. Kollert, G. Zissel, and J. Müller-Quernheim. 2007. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 56: 1685-1693. (Pubitemid 46764100)
37. Prasse, A., C. Probst, E. Bargagli, G. Zissel, G. B. Toews, K. R. Flaherty, M. Olschewski, P. Rottoli, and J. Müller-Quernheim. 2009. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179: 717-723.
38. Oh, C. K., G. P. Geba, and N.Molfino. 2010. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur. Respir. Rev. 19: 46-54.
39. Walker, W., G. D. Healey, and J. M. Hopkin. 2009. RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology 127: 256-266.
40. Woodruff, P. G., H. A. Boushey, G. M. Dolganov, C. S. Barker, Y. H. Yang, S. Donnelly, A. Ellwanger, S. S. Sidhu, T. P. Dao-Pick, C. Pantoja, et al. 2007. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc. Natl. Acad. Sci. USA 104: 15858-15863. (Pubitemid 350035389)
41. Kodelja, V., C. Müller, O. Politz, N. Hakij, C. E. Orfanos, and S. Goerdt. 1998. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1a with a Th2-associated expression pattern. J. Immunol. 160: 1411-1418. (Pubitemid 28093442)
42. Song, E., N. Ouyang, M. Hörbelt, B. Antus, M. Wang, and M. S. Exton. 2000. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell. Immunol. 204: 19-28.
43. Gauvreau, G. M., L. P. Boulet, D. W. Cockcroft, J. M. Fitzgerald, C. Carlsten, B. E. Davis, F. Deschesnes, M. Duong, B. L. Durn, K. J. Howie, et al. 2011. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183: 1007-1014.
44. Kasaian, M. T., D. Raible, K. Marquette, T. A. Cook, S. Zhou, X. Y. Tan, and L. Tchistiakova. 2011. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2. J. Immunol. 187: 561-569.
45. Kasaian, M. T., X. Y. Tan, M. Jin, L. Fitz, K. Marquette, N. Wood, T. A. Cook, J. Lee, A. Widom, R. Agostinelli, et al. 2008. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 325: 882-892. (Pubitemid 351724334)
46. Wenzel, S., L. Ford, D. Pearlman, S. Spector, L. Sher, F. Skobieranda, L. Wang, S. Kirkesseli, R. Rocklin, B. Bock, et al. 2013. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368: 2455-2466.